〔Abstract〕 Objective To study the expression and clinical significance of long non-coding RNA FEZ family(lncRNA FEZF1-AS1) in glioma tissues,and to explore the biological function of FEZF1-AS1 in gliomas. Methods qRT-PCR was used to detect the expression of FEZF1-AS1 in 60 glioma tissues and 40 normal brain tissues,and the relationship between the expression of FEZF1-AS1 in glioma tissues and clinical pathological parameters was analyzed. Kaplan-Meier survival curve analyzed the effect of FEZF1-AS1 expression on patient prognosis. FEZF1-AS1 shRNA transfected glioma cell line U87 inhibited the expression of FEZF1-AS1,MTS assay was used to detect cell proliferation. Boyden assay was used to detect cell invasion. TOP/FOP reporter gene detection was used to detect Wnt/β-catenin signaling pathway. Western blot was used to detect the expression of β-catenin protein in cells. Results The expression of FEZF1-AS1 in glioma tissues was higher than that in normal brain tissues. The high expression of FEZF1-AS1 was associated with WHO clinical classification. The glioma patients with high FEZF1-AS1 expression had shorter survival time. After interfering with the expression of FEZF1-AS1 in U87 cells,the proliferation and invasion ability of cells decreased,the luciferase activity of TOP/FOP reporter gene decreased,and the protein expression of β-catenin decreased. Conclusion The expression of FEZF1-AS1 is up-regulated in glioma tissues,and its expression level is related to WHO clinical grade and poor prognosis. Interfering with the expression of FEZF1-AS1 in glioma cells may inhibit cell proliferation and invasion by regulating Wnt/β-catenin signaling pathway.